Pipelines
We are developing drugs with minimal side effects and high efficacy with the aim of contributing to the treatment of intractable diseases with high unmet medical needs. In particular, we are focusing on the research and development of drugs that have fewer adverse events (side effects) and can be administered long-term, so that they can be safely prescribed to children, the elderly, and patients with comorbidities.
Our drug targets (lead compounds) are bioactive substances derived from probiotics (effective microorganisms). We are conducting research and development of candidate substances for new therapeutic agents utilizing probiotic-derived bioactive substances in the gastrointestinal and anticancer fields.
We aim to develop "probiotic medicines" from probiotic-derived bioactive substances with high safety by taking a full-scale approach to drug discovery, effectively utilizing our probiotic-derived bioactive substance discovery technology.